“ GLP-1 and GIP integrate nutrient-derived signals to control food intake, energy absorption,
and assimilation. This review focuses on the mechanisms regulating the
synthesis, secretion, biological actions, and
therapeutic relevance of the incretin peptides glucose-dependent insulinotropic polypeptide
(GIP) and glucagon-like peptide-1 (GLP-1). Critically,
this does not affect the glucagon response to hypoglycemia as
this effect is also glucose-dependent. However, GLP-1s also have effects that don’t depend on beta cells-they slow digestion, curb appetite and reduce glucagon levels.
GLP-1s trigger hormone-like changes in your digestive tract
and brain. GLP-1s turn down that chatter in the brain. These
effects on both the stomach and the brain are why GLP-1 analogues like Ozempic and Mounjaro have been so effective in helping patients lose weight.
Semaglutide is the active ingredient in Ozempic and
Wegovy. That’s where GLP-1 medications like Wegovy® (semaglutide) and Zepbound® (tirzepatide) come in. Ozempic, a GLP-1 medication for
type 2 diabetes, contains semaglutide as its active ingredient, the same ingredient found in Wegovy, which
is FDA-approved for weight management. ”